Posted On: July 22, 2010
Aquapharm Biodiscovery, a leading marine biotechnology company, has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its extensive collection of marine micro-organisms.
Under the terms of this agreement, drawing on its substantial experience and expertise from previous screening campaigns with its terrestrial natural products library, AMRI will screen Aquapharm’s library against Gram-negative and Gram-positive bacteria and an undisclosed anti-inflammatory target and will isolate and elucidate the structures of novel hits. Aquapharm retains all rights to compounds resulting from the collaboration.
More info
